Search Page

1

Cite

Share

Images in cardiovascular medicine. Intermittent loss of second heart sound.

Joshi J, Wechalekar AD, Bourdillon PJ, Joshi RP, Rahemtulla A, Hawkins PN. Joshi J, et al. Among authors: wechalekar ad. Circulation. 2006 Nov 28;114(22):e612-3. doi: 10.1161/CIRCULATIONAHA.106.638510. Circulation. 2006. PMID: 17130350 No abstract available.

Cite

Share

2

Cite

Share

Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis.

Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J, Pepys MB, Hawkins PN. Gillmore JD, et al. Among authors: wechalekar ad. Blood. 2006 Feb 1;107(3):1227-9. doi: 10.1182/blood-2005-08-3253. Epub 2005 Oct 6. Blood. 2006. PMID: 16210334 Free article.

Cite

Share

3

Cite

Share

Outcome of autologous stem cell transplantation for AL amyloidosis in the UK.

Goodman HJ, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN. Goodman HJ, et al. Among authors: wechalekar ad. Br J Haematol. 2006 Aug;134(4):417-25. doi: 10.1111/j.1365-2141.2006.06204.x. Epub 2006 Jul 5. Br J Haematol. 2006. PMID: 16822290

Cite

Share

4

Cite

Share

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.

Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Wechalekar AD, et al. Blood. 2007 Jan 15;109(2):457-64. doi: 10.1182/blood-2006-07-035352. Epub 2006 Sep 21. Blood. 2007. PMID: 16990593 Free article. Clinical Trial.

Cite

Share

5

Cite

Share

Perspectives in treatment of AL amyloidosis.

Wechalekar AD, Hawkins PN, Gillmore JD. Wechalekar AD, et al. Br J Haematol. 2008 Feb;140(4):365-77. doi: 10.1111/j.1365-2141.2007.06936.x. Epub 2007 Dec 19. Br J Haematol. 2008. PMID: 18162121 Review.

Cite

Share

6

Cite

Share

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.

Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Wechalekar AD, et al. Haematologica. 2008 Feb;93(2):295-8. doi: 10.3324/haematol.11627. Haematologica. 2008. PMID: 18245653 Free article.

Cite

Share

7

Cite

Share

Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis.

Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH, Li LS, Wechalekar A, Hawkins PN. Gillmore JD, et al. J Am Soc Nephrol. 2009 Feb;20(2):444-51. doi: 10.1681/ASN.2008060614. Epub 2008 Dec 10. J Am Soc Nephrol. 2009. PMID: 19073821 Free PMC article.

Cite

Share

8

Cite

Share

Solid organ transplantation in AL amyloidosis.

Sattianayagam PT, Gibbs SD, Pinney JH, Wechalekar AD, Lachmann HJ, Whelan CJ, Gilbertson JA, Hawkins PN, Gillmore JD. Sattianayagam PT, et al. Among authors: wechalekar ad. Am J Transplant. 2010 Sep;10(9):2124-31. doi: 10.1111/j.1600-6143.2010.03227.x. Am J Transplant. 2010. PMID: 20883547 Free article.

Cite

Share

9

Cite

Share

ASCT for AL: all's well that ends well.

Wechalekar AD. Wechalekar AD. Blood. 2011 Oct 20;118(16):4298-9. doi: 10.1182/blood-2011-08-375105. Blood. 2011. PMID: 22021449 Free article. No abstract available.

Cite

Share

10

Cite

Share

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.

Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD. Venner CP, et al. Among authors: wechalekar ad. Blood. 2012 May 10;119(19):4387-90. doi: 10.1182/blood-2011-10-388462. Epub 2012 Feb 13. Blood. 2012. PMID: 22331187 Free article.

Cite

Share